Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Schering gets non-US rights to Idec's Zevalin

Executive Summary

Schering AG licensed exclusive worldwide marketing rights outside of the US to Idec's (monoclonal antibodies) Zevalin (ibritumomab tiuxetan, formerly IDEC-Y2B8) in a deal worth up to $47.5mm to Idec. Schering paid (uf)$13mm up front and will pay $15mm more in committed funds. Idec could also get $19.5mm more in milestones, as well as royalties on sales.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies